Aktienanalyse zu OraSure Technologies Inc (OSUR)OSUROraSure Technologies Inc

OraSure Technologies, Inc. transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. The Company, together with its wholly owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., is engaged in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. Its products and services include OraQuick ADVANCE Rapid HIV 1/2 Antibody Test, OraQuick HIV Self-Test, Diagnostics Direct Syphilis Health Check, OraQuick Ebola Rapid Antigen Test, InteliSwab COVID-19 Rapid Test Pro, and SickleSCAN Test, among others. Its portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct consumers. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

OraSure Technologies Inc is not a good buy right now due to its current price of 3.6, which is near its 200-day simple moving average of 3.225, indicating potential weakness. Additionally, the RSI is at 27.459, suggesting the stock is oversold, but this could also indicate continued downward pressure. The recent hedge fund selling increased by 2277.40%, indicating a lack of confidence among institutional investors, which is a significant risk factor.

5 analysts cover OSUR: 4 rate it Buy, 1 Hold and 0 Sell.